Tuesday, May 03, 2022 12:44:28 PM
So big pharma... Pfizer received an emergency use authorization for Paxlovid before any real proof that it actually works! The FDA has some serious corruption and it is affecting the health of Americans. Government run agencies are not exactly full of the brightest and best of people. Political influence, graft, corruption and special future employment favors... all influence their decisions.
Pfizer Inc. slumped after Paxlovid, its pill for treating Covid-19, failed to show benefit as a preventive therapy in a trial.
https://finance.yahoo.com/news/pfizer-falls-covid-pill-fails-130238318.html
"Paxlovid is poised to become one of the fastest-selling drugs of all time, with $24 billion in projected 2022 sales, according to analytics group Airfinity Ltd. Pfizer has also reaped billions in global sales from its Covid-19 vaccine.
The company said late Friday that the drug failed to hit its main goal of reducing the risk that adults exposed to the coronavirus through contact with a household member would become infected. Compared with those who took a placebo, people who received Paxlovid had about a third less risk of infection, which wasn’t statistically significant.
The shares fell 2.2% at 9:36 a.m. in New York. They had declined 17% this year through Friday’s close.
The trial failure, along with reports of rebounding coronavirus levels in some patients who have completed a course of Paxlovid, are unlikely to change the drug’s sales potential, according to Bloomberg Intelligence analysts John Murphy and Sam Fazeli.
“The trial miss at most takes away a small incremental sales opportunity in future years,” they said Monday in a research note. The reports of rebound infections are “also not surprising as viral dynamics during an infection are unlikely to fit perfectly with a rigid 5-day course.”
Morgan Stanley analysts, who had estimated the drug’s sales to reach $48 billion in 2022, said the prophylaxis data might affect their forecast."
Pfizer Inc. slumped after Paxlovid, its pill for treating Covid-19, failed to show benefit as a preventive therapy in a trial.
https://finance.yahoo.com/news/pfizer-falls-covid-pill-fails-130238318.html
"Paxlovid is poised to become one of the fastest-selling drugs of all time, with $24 billion in projected 2022 sales, according to analytics group Airfinity Ltd. Pfizer has also reaped billions in global sales from its Covid-19 vaccine.
The company said late Friday that the drug failed to hit its main goal of reducing the risk that adults exposed to the coronavirus through contact with a household member would become infected. Compared with those who took a placebo, people who received Paxlovid had about a third less risk of infection, which wasn’t statistically significant.
The shares fell 2.2% at 9:36 a.m. in New York. They had declined 17% this year through Friday’s close.
The trial failure, along with reports of rebounding coronavirus levels in some patients who have completed a course of Paxlovid, are unlikely to change the drug’s sales potential, according to Bloomberg Intelligence analysts John Murphy and Sam Fazeli.
“The trial miss at most takes away a small incremental sales opportunity in future years,” they said Monday in a research note. The reports of rebound infections are “also not surprising as viral dynamics during an infection are unlikely to fit perfectly with a rigid 5-day course.”
Morgan Stanley analysts, who had estimated the drug’s sales to reach $48 billion in 2022, said the prophylaxis data might affect their forecast."
Recent NRXP News
- NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 • GlobeNewswire Inc. • 05/28/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System • GlobeNewswire Inc. • 05/27/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/18/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality • GlobeNewswire Inc. • 05/07/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 04/06/2026 11:00:00 AM
- Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application • GlobeNewswire Inc. • 03/17/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date • GlobeNewswire Inc. • 01/16/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval • GlobeNewswire Inc. • 01/14/2026 12:03:00 PM
- NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions • GlobeNewswire Inc. • 01/05/2026 11:57:00 AM
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion • GlobeNewswire Inc. • 12/18/2025 12:05:00 PM
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation • GlobeNewswire Inc. • 12/03/2025 12:00:00 PM
- NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine • GlobeNewswire Inc. • 12/02/2025 01:30:00 PM
